These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 17455364)
21. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals. Murnane D; Martin GP; Marriott C J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819 [TBL] [Abstract][Full Text] [Related]
22. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Iida K; Inagaki Y; Todo H; Okamoto H; Danjo K; Luenberger H Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):938-42. PubMed ID: 15304985 [TBL] [Abstract][Full Text] [Related]
23. Aerodynamic and electrostatic properties of model dry powder aerosols: a comprehensive study of formulation factors. Telko MJ; Hickey AJ AAPS PharmSciTech; 2014 Dec; 15(6):1378-97. PubMed ID: 24938617 [TBL] [Abstract][Full Text] [Related]
24. Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems. Young PM; Sung A; Traini D; Kwok P; Chiou H; Chan HK Pharm Res; 2007 May; 24(5):963-70. PubMed ID: 17377746 [TBL] [Abstract][Full Text] [Related]
25. Dry powder aerosol delivery systems: current and future research directions. Chan HK J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211 [TBL] [Abstract][Full Text] [Related]
26. Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate. Le VN; Hoang Thi TH; Robins E; Flament MP AAPS PharmSciTech; 2012 Jun; 13(2):477-84. PubMed ID: 22399285 [TBL] [Abstract][Full Text] [Related]
27. The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation. Lee HJ; Lee HG; Kwon YB; Kim JY; Rhee YS; Chon J; Park ES; Kim DW; Park CW Eur J Pharm Sci; 2018 May; 117():279-289. PubMed ID: 29510172 [TBL] [Abstract][Full Text] [Related]
28. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation. Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413 [TBL] [Abstract][Full Text] [Related]
29. Lactose characteristics and the generation of the aerosol. Pilcer G; Wauthoz N; Amighi K Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107 [TBL] [Abstract][Full Text] [Related]
30. Effect of Roughness on the Dispersion of Dry Powders for Inhalation: a Dynamic Visualization Perspective. Kou X; Heng PWS; Chan LW; Wereley ST; Carvajal MT AAPS PharmSciTech; 2019 Jul; 20(7):271. PubMed ID: 31363868 [TBL] [Abstract][Full Text] [Related]
31. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices. Ooi J; Gill C; Young PM; Traini D Curr Drug Deliv; 2015; 12(1):40-6. PubMed ID: 25146438 [TBL] [Abstract][Full Text] [Related]
32. Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders. Raula J; Thielmann F; Naderi M; Lehto VP; Kauppinen EI Int J Pharm; 2010 Jan; 385(1-2):79-85. PubMed ID: 19879344 [TBL] [Abstract][Full Text] [Related]
33. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier. Hassan MS; Lau R Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775 [TBL] [Abstract][Full Text] [Related]
34. The effect of relative humidity on electrostatic charge decay of drugs and excipient used in dry powder inhaler formulation. Elajnaf A; Carter P; Rowley G Drug Dev Ind Pharm; 2007 Sep; 33(9):967-74. PubMed ID: 17891583 [TBL] [Abstract][Full Text] [Related]
35. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier. Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):444-6. PubMed ID: 15056961 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier. Iida K; Hayakawa Y; Okamoto H; Danjo K; Leuenberger H Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1326-30. PubMed ID: 11605663 [TBL] [Abstract][Full Text] [Related]
37. Assessment of Dry Powder Inhaler Carrier Targeted Design: A Comparative Case Study of Diverse Anomeric Compositions and Physical Properties of Lactose. Pinto JT; Zellnitz S; Guidi T; Roblegg E; Paudel A Mol Pharm; 2018 Jul; 15(7):2827-2839. PubMed ID: 29856921 [TBL] [Abstract][Full Text] [Related]
38. What is the role of particle morphology in pharmaceutical powder aerosols? Chan HK Expert Opin Drug Deliv; 2008 Aug; 5(8):909-14. PubMed ID: 18712999 [TBL] [Abstract][Full Text] [Related]
39. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate. Thi TH; Danède F; Descamps M; Flament MP Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size. Du P; Du J; Smyth HD AAPS PharmSciTech; 2014 Dec; 15(6):1417-28. PubMed ID: 24962007 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]